Business news for the stock market

4basebio AG: Update regarding the status of the settlement of the spin-off

Heidelberg (pta026/17.12.2020/11:15 UTC+1) 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announces that the formal application of the transfer of the registered office and the registration of 4basebio SE at the Companies House of England and Wales is in process. Both the technical settlement of the spin-off and the commencement of stock exchange trading for the 12,317,473 shares of 4basebio SE are currently expected to occur in the course of January 2021.

As already explained in the press release of 8 December 2020, until the registration of 4basebio SE in Companies House and the subsequent admission of the shares of 4basebio SE in the central securities depository CREST, the listing of the shares of 4basebio AG in the regulated market on the stock exchange in Frankfurt am Main and in the open market on all other German stock exchanges will still be "cum" spin-off, i.e. if 4basebio AG shares are traded, then the respective 4basebio AG shares comprise the right to the 4basebio SE shares or partial rights to 4basebio SE shares pertaining hereto as consideration for the spin-off. Thus, the 4basebio AG shares admitted to stock exchange trading still represent a participation in the business activities spun off to 4basebio SE until the banks have completed the technical settlement process for the spin-off.

The exact date of the technical separation of the 4basebio SE shares from the 4basebio AG shares at the stock market ("Ex day"), which is currently expected to occur in January 2021, will be announced with a separate allocation announcement in the Federal Gazette and a further corporate news release, after the registration of the transfer of the registered office has taken place. The 4basebio AG shareholders do not need to take any own actions for purposes of the subsequent settlement and allocation process for the 4basebio SE shares.

For further information, please contact:
4basebio AG
Dr. Heikki Lanckriet, Executive Management Board Member
Phone: +44 1223 873 364

Dr. Robert Mayer, Manager IR
Phone: +49 171 3876540

MC Services AG (Investor Relations and International Media Relations)
Julia Hofmann
Phone: +49 89 210228 0

About 4basebio AG:

4basebio AG (previously Expedeon AG) sold its immunology and proteomics businesses to Abcam plc on 1 January 2020. Following the spin-off of its remaining genomics business into 4basebio SE on 8 December 2020, the Company will focus on the deployment of its cash resources into suitable investment opportunities within the biotech sector and in other areas, alongside its 30% stake in 4basebio SE. 4basebio AG is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).

More information:

# # # This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. # # #


Emitter: 4basebio AG
Waldhofer Str. 102
69123 Heidelberg
Contact Person: Robert Mayer
Phone: +49 171 3876540
ISIN(s): DE000A2YN801 (Share)
Stock Exchange(s): Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate